Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer

ABSTRACT:

SUBMITTER: Bajpai P

PROVIDER: S-EPMC11238352 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Combination of dual JAK/HDAC inhibitor with regorafenib reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer

Project description:To evaluate the differential gene expression contributing to the efficacy of the combination treatment of JAK/HDAC inhibitor with regorafenib, compared to single drug treatment, we performed the RNA-sequencing

2024-07-17 | GSE252554 | GEO

Combination of dual JAK/HDAC inhibitor with regorafenib reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer

Project description:Combination of dual JAK/HDAC inhibitor with regorafenib reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer

| PRJNA1061163 | ENA

JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Project description: Not available

| S-EPMC7252559 | biostudies-literature

Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.

Project description: Not available

| S-EPMC8307450 | biostudies-literature

Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.

Project description: Not available

| S-EPMC7864865 | biostudies-literature

A Gly-β-muricholic acid and FGF15 combination therapy synergistically reduces "humanized" bile acid pool toxicity in cholestasis mice.

Project description: Not available